Kanglaite Injection (KLT) is a botanical anticancer drug prepared as a micro-emulsion for intravenous use. It is produced by the state of art technology with active substance extracted from a natural herbal plant called "semen coicis".

As a novel antineoplastic agent KLT has the following features.
- Killing cancer cells directly and effectively while remarkably improving patient immune function;
- Synergistic in increasing efficacy and in reducing toxicity when combined with chemotherapy regimens or radiation therapy;
- Providing high energy nutrition to treat cachexia;
- Relieving cancerous pain markedly;
- Improving patient quality of life and notably prolonging survival;
- With little adverse reaction itself

KLT has brought great benefits to over 550,000 cancer patients in more than 2,200 hospitals in China. It has become the market leader among all anticancer drugs in China in recent 4 years.

FDA approved KLT clinical study in USA in March 2001 and the phase I study at Huntsman Cancer Institute, Salt Lake City, Utah was satisfactorily completed the year later.

Russian Federation approved KLT clinical study in January 2002 and the clinical studies were smoothly ended in April 2003 with very inspiring outcomes. In December 2003 the registration certificate was issued from Russian Ministry of Health and KLT has been launched in Russia from July 2005.

Unique anticancer mechanisms of KLT have been verified by famous researchers at Johns Hopkins University, USA.